http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오늘 본 자료
Kim, Hyeong Seok,Han, Youngmin,Kang, Jae Seung,Kim, Hongbeom,Kim, Jae Ri,Koon, Wooil,Kim, Sun‐,Whe,Jang, Jin‐,Young John WileySons Ltd 2018 Journal of hepato-biliary-pancreatic sciences Vol.25 No.2
<P>ConclusionRobot PD is comparable to open PD in early outcomes. Robot PD is safe and feasible and enables early recovery; indication for robot PD is expected to expand in the near future.</P>
Kim, Hyeong Seok,Jang, Jin-Young,Han, Youngmin,Lee, Kyoung Bun,Joo, Ijin,Lee, Doo-Ho,Kim, Jae Ri,Kim, Hongbeom,Kwon, Wooil,Kim, Sun-Whe The Korean Surgical Society 2017 Annals of Surgical Treatment and Research(ASRT) Vol.93 No.4
<P><B>Purpose</B></P><P>Neoadjuvant treatment may provide improved survival outcomes for patients with borderline resectable pancreatic cancer (BRPC). The purpose of this study is to evaluate the clinical outcomes of neoadjuvant treatment and to identify prognostic factors.</P><P><B>Methods</B></P><P>Forty patients who met the National Comprehensive Cancer Network definition of BRPC and received neoadjuvant treatment followed by surgery between 2007 and 2015 were evaluated. Prospectively collected clinicopathological outcomes were analyzed retrospectively.</P><P><B>Results</B></P><P>The mean age was 61.7 years and the male-to-female ratio was 1.8:1. Twenty-six, 3, and 11 patients received gemcitabine-based chemotherapy, 5-fluorouracil, and FOLFIRINOX, respectively. The 2-year survival rate (2YSR) was 36.6% and the median overall survival (OS) was 20 months. Of the 40 patients, 34 patients underwent resection and the 2YSR was 41.2% while the 2YSR of patients who did not undergo resection was 16.7% (P = 0.011). The 2YSR was significantly higher in patients who had partial response compared to stable disease (60.6% <I>vs</I>. 24.3%, P = 0.038), in patients who did than did not show a CA 19-9 response after neoadjuvant treatment (40.5% <I>vs</I>. 0%, P = 0.039) and in patients who did than did not receive radiotherapy (50.8% <I>vs</I>. 25.3%, P = 0.036). Five patients had local recurrence and 17 patients had systemic recurrence with a median disease specific survival of 15 months.</P><P><B>Conclusion</B></P><P>Neoadjuvant treatment followed by resection is effective for BRPC. Pancreatectomy and neoadjuvant treatment response may affect survival. Effective systemic therapy is needed to improve long-term survival since systemic metastasis accounts for a high proportion of recurrence.</P>
Wooil Kim,Daeun Kim,Sanggeun Back,Yong-Suk Lee,Afrouzossadat Hosseini Abari,Junehyung Kim 한국생물공학회 2019 Biotechnology and Bioprocess Engineering Vol.24 No.2
In this paper, we report removing heavy metal using Bacillus subtilis spore surface display system. We used CotE protein as an anchoring motif because of its high abundance and location in the outer coat layer. And we inserted His12 (double histidine 6 tag) at the C-terminal end of anchoring motif. The proper expression of CotEHis12 fusion protein (22.8 kDa) was confirmed by western blot. We confirmed the surface expression of the CotEHis12 fusion protein using flow cytometry. We tried Ni2+ and Cd2+ adsorption with recombinant spore DB104 (pCotE-His12) and DB104 spore. The amount of adsorbed Ni2+ was 18.2 nmol/mg for DB104 spore and 82.4 nmol/mg for DB104 (pCotE-His12) spore. In the case of Cd2+, the adsorbed amount was 32.6 nmol/mg for DB104 spore and 79.1 nmol/mg for DB104 (pCotE-His12) spore. This means that our spore displayed His12 system can be generally applied for the removal of various kind of heavy metals in the field.
Kim Wooil,Lee Sang Min,Lee Jung Bok,Seo Joon Beom,Kim Hong Kwan,Kim Jhingook,Lee Ho Yun 대한영상의학회 2022 Korean Journal of Radiology Vol.23 No.3
Objective: To compare pneumonic-type invasive mucinous adenocarcinoma (pIMA) confined to a single lobe with clinical T2, T3, and T4 stage lung cancer without pathological node metastasis regarding survival after curative surgery and to identify prognostic factors for pIMA. Materials and Methods: From January 2010 to December 2017, 41 patients (15 male; mean age ± standard deviation, 66.0 ± 9.9 years) who had pIMA confined to a single lobe on computed tomography (CT) and underwent curative surgery were identified in two tertiary hospitals. Three hundred and thirteen patients (222 male; 66.3 ± 9.4 years) who had non-small cell lung cancer (NSCLC) without pathological node metastasis and underwent curative surgery in one participating institution formed a reference group. Relapse-free survival (RFS) and overall survival (OS) were calculated using the Kaplan–Meier method. Cox proportional hazard regression analysis was performed to identify factors associated with the survival of patients with pIMA. Results: The 5-year RFS and OS rates in patients with pIMA were 33.1% and 56.0%, respectively, compared with 74.3% and 91%, 64.3% and 71.8%, and 46.9% and 49.5% for patients with clinical stage T2, T3, and T4 NSCLC in the reference group, respectively. The RFS of patients with pIMA was comparable to that of patients with clinical stage T4 NSCLC and significantly worse than that of patients with clinical stage T3 NSCLC (p = 0.012). The differences in OS between patients with pIMA and those with clinical stage T3 or T4 NSCLC were not significant (p = 0.11 and p = 0.37, respectively). In patients with pIMA, the presence of separate nodules was a significant factor associated with poor RFS and OS {unadjusted hazard ratio (HR), 4.66 (95% confidence interval [CI], 1.95–11.11), p < 0.001 for RFS; adjusted HR, 4.53 (95% CI, 1.59–12.89), p = 0.005 for OS}. Conclusion: The RFS of patients with pIMA was comparable to that of patients with clinical stage T4 lung cancer. Separate nodules on CT were associated with poor RFS and OS in patients with pIMA.
Hyeong Seok Kim,Jin-Young Jang,Youngmin Han,Kyoung Bun Lee,Ijin Joo,Doo-Ho Lee,Jae Ri Kim,Hongbeom Kim,Wooil Kwon,Sun-Whe Kim 대한외과학회 2017 Annals of Surgical Treatment and Research(ASRT) Vol.93 No.4
Purpose: Neoadjuvant treatment may provide improved survival outcomes for patients with borderline resectable pancreatic cancer (BRPC). The purpose of this study is to evaluate the clinical outcomes of neoadjuvant treatment and to identify prognostic factors. Methods: Forty patients who met the National Comprehensive Cancer Network definition of BRPC and received neoadjuvant treatment followed by surgery between 2007 and 2015 were evaluated. Prospectively collected clinicopathological outcomes were analyzed retrospectively. Results: The mean age was 61.7 years and the male-to-female ratio was 1.8:1. Twenty-six, 3, and 11 patients received gemcitabine-based chemotherapy, 5-fluorouracil, and FOLFIRINOX, respectively. The 2-year survival rate (2YSR) was 36.6% and the median overall survival (OS) was 20 months. Of the 40 patients, 34 patients underwent resection and the 2YSR was 41.2% while the 2YSR of patients who did not undergo resection was 16.7% (P = 0.011). The 2YSR was significantly higher in patients who had partial response compared to stable disease (60.6% vs. 24.3%, P = 0.038), in patients who did than did not show a CA 19-9 response after neoadjuvant treatment (40.5% vs. 0%, P = 0.039) and in patients who did than did not receive radiotherapy (50.8% vs. 25.3%, P = 0.036). Five patients had local recurrence and 17 patients had systemic recurrence with a median disease specific survival of 15 months. Conclusion: Neoadjuvant treatment followed by resection is effective for BRPC. Pancreatectomy and neoadjuvant treatment response may affect survival. Effective systemic therapy is needed to improve long-term survival since systemic metastasis accounts for a high proportion of recurrence.
The effect of sodium butyrate for AKR1C3 expression in melanoma
( Wooil Kim ),( Kyurak Hong ),( Ayoung Park ),( Jongsuk Lee ),( Sooyoung Kim ),( Kyuuang Whang ),( Moonkyun Cho ) 대한피부과학회 2019 대한피부과학회 학술발표대회집 Vol.71 No.2
Background: The AKR family 1 member C3 (AKR1C3) was known to act as antioxidant and indirectly govern ligand access to various receptors and regulate the trans-activational activities of these nuclear receptors. Deregulated expression of AKR1C3 has been reported in multiple types of cancers. But there is no report on the expression of AKR1C3 in melanoma. Objectives: To figure out expression level of AKR1C3 in vivo and relation between sodium butyrate (NaBu) and AKR1C3 in vitro in melanoma. Methods: We investigated the expression levels of AKR1C3 in 6 human cutaneous melanoma tissues and 10 normal skin tissues by immunohistochemical staining and western blotting, while measuring expression levels of AKR1C3 in human melanoma cell G361, SK-MEL24 and human cervical cancer cell Hela, following NaBu treatment. Results: The results showed the downregulation of AKR1C3 in melanoma. Also we found decreased expression of AKR1C3 in human melanoma cell G361. Histone modification is known to be an essential regulatory mechanism associated with various genetic processes. Here we demonstrated upregulation of AKR1C3 in G361 cells following treatment with NaBu known as HDAC inhibitor. Conclusion: Our results showed that downregulation of AKR1C3 expression may be associated with melanoma development. We also demonstrated that inhibition of histone deacetylation following NaBu treatment increased AKR1C3 expression in melanoma cells. But further studies are needed to know the exact role of AKR1C3 in melanoma.
Application of Dual-Energy Spectral Computed Tomography to Thoracic Oncology Imaging
Kim Cherry,Kim Wooil,Park Sung-Joon,Lee Young Hen,Hwang Sung Ho,Yong Hwan Seok,Oh Yu-Whan,Kang Eun-Young,Lee Ki Yeol 대한영상의학회 2020 Korean Journal of Radiology Vol.21 No.7
Computed tomography (CT) is an important imaging modality in evaluating thoracic malignancies. The clinical utility of dual-energy spectral computed tomography (DESCT) has recently been realized. DESCT allows for virtual monoenergetic or monochromatic imaging, virtual non-contrast or unenhanced imaging, iodine concentration measurement, and effective atomic number (Zeff map). The application of information gained using this technique in the field of thoracic oncology is important, and therefore many studies have been conducted to explore the use of DESCT in the evaluation and management of thoracic malignancies. Here we summarize and review recent DESCT studies on clinical applications related to thoracic oncology.